Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 1783  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Resource Links
  »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
  »  Article in PDF (686 KB)
  »  Citation Manager
  »  Access Statistics
  »  Reader Comments
  »  Email Alert *
  »  Add to My List *
* Registration required (free)  

  In this Article
 »  Abstract
 » Introduction
 »  Materials and Me...
 » Results
 » Discussion
 »  References
 »  Article Figures
 »  Article Tables

 Article Access Statistics
    PDF Downloaded82    
    Comments [Add]    
    Cited by others 3    

Recommend this journal


Table of Contents    
Year : 2012  |  Volume : 60  |  Issue : 4  |  Page : 400-405

Safety and efficacy of mechanical thrombectomy with the Solitaire device in large artery occlusion

1 Department of Neurology, Inje University, Ilsan Paik Hospital, Gyeonggi-do, South Korea
2 Department of Neurology; Stroke Center, Inje University, Ilsan Paik Hospital, Gyeonggi-do, South Korea
3 Stroke Center; Department of Radiology, Inje University, Ilsan Paik Hospital, Gyeonggi-do, South Korea

Date of Submission06-Jun-2012
Date of Decision07-Jul-2012
Date of Acceptance30-Jul-2012
Date of Web Publication6-Sep-2012

Correspondence Address:
Keun-Sik Hong
Department of Neurology, Ilsan Paik Hospital, Inje University, 2240 Daewha-dong, Ilsanseo-gu, Goyang City, Gyeonggi-do
South Korea
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0028-3886.100701

Rights and Permissions

 » Abstract 

Background and Purpose: Intravenous tissue plasminogen activator (TPA) has limited efficacy in proximal large vessel occlusions. This study was to assess the safety and efficacy of mechanical thrombectomy with a retrievable Solitaire stent in acute large artery occlusions . Materials and Methods: This is a single center study enrolling patients treated with Solitaire-assisted thrombectomy between November 2010 and March 2011. Inclusion criteria were severe stroke of National Institutes of Health Stroke Scale (NIHSS) score ≥10, treatment initiation within 6 hours from onset, and an angiographically verified occlusion of proximal middle cerebral artery (MCA) or internal carotid artery (ICA). The primary outcome was recanalization defined as Thrombolysis in Cerebral Infarct (TICI) reperfusion grade 2b/3. Secondary outcomes were good functional outcome at 3 months (modified Rankin Scale [mRS] ≤2), early substantial neurological improvement (NIHSS score improvement ≥8 at 24 hours), and symptomatic hemorrhagic transformation (SHT). Results: Ten patients were consecutively enrolled: Age: 72.4 ΁ 5.7 years; female: 70%; baseline median NIHSS score: 19.5; and ICA occlusion in 50% and M1 portion of MCA occlusion in 50%. Six patients received intravenous TPA before intra-arterial treatment, and five patients were treated with adjuvant intra-arterial urokinase. Successful recanalization was achieved in 7 (70%) patients. Four (40%) patients had a good functional outcome at 3 months, and three (30%) patients had an early substantial neurological improvement. SHT occurred in two patients (20%), and 3-month mortality rate was 30%. There was no procedure-related complication. Conclusions: Mechanical thrombectomy with the Solitaire device can effectively recanalize proximal large vessel occlusions, and potentially improves clinical outcome.

Keywords: Stent, stroke, thrombectomy, thrombolysis

How to cite this article:
Kim JE, Kim AR, Paek YM, Cho YJ, Lee BH, Hong KS. Safety and efficacy of mechanical thrombectomy with the Solitaire device in large artery occlusion. Neurol India 2012;60:400-5

How to cite this URL:
Kim JE, Kim AR, Paek YM, Cho YJ, Lee BH, Hong KS. Safety and efficacy of mechanical thrombectomy with the Solitaire device in large artery occlusion. Neurol India [serial online] 2012 [cited 2023 Mar 29];60:400-5. Available from: https://www.neurologyindia.com/text.asp?2012/60/4/400/100701

 » Introduction Top

Acute stroke due to a large vessel occlusion is a catastrophe, usually destined to death or severe disability. With intravenous tissue plasminogen activator (tPA) therapy, the recanalization rate was only 10% in internal carotid artery (ICA) occlusion and less than 30% for proximal middle cerebral artery (M1 portion of MCA) occlusion. [1],[2] For severe strokes of NIHSS score ≥16, even after intravenous TPA, one third died, another one third remained severely disabled (modified Rankin Scale [mRS] 4-5), and only one-fourth of patients were independent (mRS 0-2) at 3 months. If not treated with TPA, the chance of good outcome further decreased to 18%. [3].[4].[5]

Intra-arterial (IA) thrombolysis is a promising option for acute large arterial occlusions. Several trials and a meta-analysis have indicated that IA fibrinolysis substantially increases recanalization rates and good and excellent clinical outcomes. [6],[7],[8] However, a large thrombus is quite resistant to a standard microcatheter thrombolysis technique and usually require a prolonged time for recanalization, which would fail to improve outcomes even after achieving recanalization. [9],[10],[11],[12] Accordingly, new thrombectomy devices have been developed to recanalize large vessel occlusions more successfully and more rapidly. [13],[14],[15],[16],[17] The Solitaire AB (ev3 Inc, Plymouth, MN) is a self-expanding and fully retrievable stent that can be used as a thrombectomy device for large arterial occlusions. Recent studies have shown encouraging results of high recanalization rates. [17],[18] This study is to report safety and efficacy of the Solitaire thrombectomy device in patients with severe acute ischemic stroke due to proximal large vessel occlusions.

 » Materials and Methods Top


This is a single center study of mechanical thrombectomy with the Solitaire device (Solitaire AB; ev3 Inc, Plymouth, MN), and patients were enrolled between November 2010 and March 2011. Our thrombolysis protocol for patient selection is given in [Figure 1]. Inclusion criteria were (1) age ≥18 years, (2) baseline NIHSS ≥10, (3) angiographically confirmed ICA or M1 occlusion, (4) symptom duration ≤6 hours, and (5) no contraindication for reperfusion therapy. Intravenous TPA was given to patients when symptom duration was less than 4.5 hours based on the European Cooperative Acute Stroke Study (ECASS) III trial results. [19] However, intravenous TPA dose was modified to 0.6 mg/kg according to the protocol of Interventional Management of Stroke (IMS) trial. [20],[21] Informed consent was obtained from patients, family members, or surrogates.
Figure 1: Thrombolysis protocol for patient selection

Click here to view


Using digital subtraction angiography, we identified target vessels. We placed a 7F long sheath (Shuttle, Cook) or 8F-9F guide catheter (Envoy, Cordis) on the cervical segment of ICA or distal common carotid artery. The clot was carefully passed with a 0.014-inch guide wire (Traxcess, ev3 or Agility, Cordis). A microcatheter (Rebar-18 ev3, or Prowler Select Plus, Cordis) was navigated over the wire just distal to the thrombus under fluoroscopic control. After placement of microcatheter beyond the thrombus, the 4 × 20 mm Solitaire device was advanced through the microcatheter and deployed to cover the entire vessel segment where the thrombus lodged. Then, we performed an angiogram to confirm successful stent unfolding and to assess immediate flow re-establishment. The stent device was kept in place for 1 to 5 minutes and then slowly retrieved. We could not use a balloon catheter to achieve flow arrest specially designed for the Solitaire device because it was not formally available in Korea. Instead, to prevent re-embolization, manual negative suction with a 50 cc syringe and simultaneous carotid compression were applied during stent retrieval. If the occlusion persisted after the first pass, the procedure was repeated and adjuvant IA urokinase infusion was considered. Maximum attempts of stent deployment and use of IA urokinase were left at the discretion of responsible neurologist and interventionalist. IA therapy was terminated when intracerebral hemorrhage was suspected or 7 hours passed from symptom onset. During the procedure, we collected data of time intervals of groin puncture, initiation and end of thrombectomy, and recanalization from symptom onset, urokinase dose, and numbers of the Solitaire device passes.

Patient evaluation and outcome measure

NIHSS scores were assessed on admission, at 24 hours after procedure and discharge, and whenever patients had a neurological deterioration. Functional outcome was assessed with mRS at discharge and at 90 days. Pre-stroke mRS disability was also obtained from interviewing family members. Computed tomography (CT) or magnetic resonance imaging (MRI) scan was performed in all patients before and 24 hours after reperfusion therapy. When patients had a neurological deterioration, an emergent CT scan was obtained.

The primary outcome was recanalization defined as Thrombolysis In Cerebral Infarction (TICI) reperfusion grade 2b or 3 on immediate post-procedural angiograms. [22] Secondary outcomes were good functional outcome at 3 months (mRS ≤2) and early substantial neurological improvement (NIHSS score improvement ≥8 at 24 hours). Safety outcomes were (1) symptomatic hemorrhagic transformation (SHT) defined as intracranial hemorrhage on CT/MRI associated with NIHSS score decline ≥4 within 24 hours, (2) device-related complications of vessel perforation, arterial dissection, or embolization to an initially uninvolved territory, and (3) any hemorrhagic transformation on follow-up imaging classified by the ECASS criteria.

 » Results Top

Patient characteristics

Ten consecutive patients (mean age: 72.4 ± 5.7 years, 7 (70%) females) were treated. Median baseline NIHSS score was 19.5 (range, 13 to 27) and there were 5 M1 and 5 ICA occlusions. Six patients (60%) received intravenous tPA before IA therapy, and five (50%) patients were treated with adjuvant IA urokinase (dose range, 40,000-200,000 U) to further recanalize distal branches. Duration of IA procedure was 80.5 ± 24.0 minutes, and the interval from onset to treatment completion was 248.0 ± 76.4 minutes. Summary of patient characteristics and the outcome of each patient are presented in [Table 1] and [Table 2].
Table 1: Baseline characteristics

Click here to view
Table 2: Individual patient data

Click here to view


Successful recanalization was achieved in 7 (70%) patients (3 M1 and 4 ICA occlusions): The TICI reperfusion grade was 3 in four patients and 2b in three patients. Median number of the Solitaire passing was 1.5 times (range, 1-3). Recanalization was achieved after one pass in five, 2 passes in one, and 3 passes in one patient.

Clinical outcomes

At 90 days, four (40%) patients had a good functional outcome (mRS 0-2). Three-month functional outcome was associated with recanalization. Of the seven recanalized patients, 4 (57.1%) had a good mRS outcome, whereas 3 patients without recanalization had a poor outcome (mRS 4 in one patient and mRS 6 in two patients) [Figure 2].
Figure 2: mRS outcome at 3 months stratified by recanalization

Click here to view

Three (30%) patients had an early substantial neurological improvement of NIHSS score decrease ≥8 at 24 hours. These three patients had a TICI reperfusion grade 3 and an excellent outcome at 90 days (mRS 0 in one and mRS 1 in two patients). Mortality rate at 3-month was 30%. The causes of death were herniation, aspiration pneumonia, and undetermined, respectively. Clinical efficacy and safety outcome is summarized in [Table 3].
Table 3: Efficacy and safety outcomes

Click here to view


Any hemorrhagic transformation within 24 hours occurred in six patients (2 hemorrhagic infarction type 1, one hemorrhagic infarction type 2, and 3 parenchymal hematoma type 2). SHT developed in two patients. One case was a 77 year-old woman with ICA occlusion and initial NIHSS score of 22. She failed to achieve recanalization, and neither intravenous TPA nor IA urokinase was administered. She died because of herniation at 3 days from stroke onset. The other case was a 74-year-old man with M1 occlusion and initial NIHSS score of 19. He received intravenous TPA and had a recanalization after thrombectomy without adjuvant IA urokinase. This patient had a decompressive surgery, but he died after discharge to a long-term care facility. In addition to two SHTs, one parenchymal hematoma type 2 was detected on follow-up CT, but it was not associated with a neurological deterioration. None of the case had a device-related complication.

 » Discussion Top

This study shows that the Solitaire device-assisted thrombectomy is a promising option for large vessel occlusions. Successful recanalization was achieved in 70%, which led to a good outcome in 40% and an early substantial neurological improvement in 30% of all treated patients. Single pass was sufficient to recanalize the primary occlusion site in five patients. Adjuvant IA urokinase was required in five patients, but these patients had recanalization from a single pass and IA urokinase was delivered to achieve a better reperfusion in distal vascular beds. Since thrombectomy alone substantially reduced thrombus burden, the required urokinase dose was small as 4 of 5 patients received ≤100,000 U (mean dose: 50,000 U). None of IA urokinase-treated patients developed SHT.

Our recanalization rate is higher than Mechanical Embolus Removal in Cerebral Ischemia (MERCI) trial result, similar to those of Prolyse in Acute Cerebral Thromboembolism (PROACT) II, IMS II, and Multi-MERCI trials, and less than those of Penumbra trial and another Solitaire study [Table 4]. [6],[13],[15],[17],[21] The frequency of good outcome in the current study is greater than those of MERCI and Penumbra trials and comparable to those of PROACT II, IMS II, Multi-MERCI trials, and another Solitaire study. It is of note that our patients were older (≥70 years in 80%) than those enrolled in other IA reperfusion studies. Considering that elderly patients are known to have poor response to treatments, our outcome result is quite encouraging.

Recently, results from the SWIFT (Solitaire With the Intention For Thrombectomy) trial comparing the efficacy and safety of Solitaire and Merci devices were presented at 2012 International Stroke Conference [23] The Solitaire group had a higher recanalization rate and achieved more good outcomes of mRS 0-2 than did the Merci group. The rates of successful recanalization (88.9%) and good outcome (58.2%) in the Solitaire group of the SWIFT trial were higher than our results. The discrepancies between the SWIFT trial and our study might reflect the difference between clinical trial and real world practice. Since clinical trial results are usually derived from highly experienced experts and selected patients, real world practice frequently fails to achieve a treatment efficacy as much as seen in clinical trials. In addition, although our patients were treated earlier than those in the SWIFT trial (167.5 vs 294 minutes), the higher age (average 72.4) and higher NIHSS score (median 19.5) of our patients as compared to those enrolled in the SWIFT trial (average age, 67; NIHSS 17.3) partially accounts for the outcome discrepancy.
Table 4: Comparison of our findings with those of prior published studies

Click here to view

To compare with intravenous tPA results, we extracted data of comparable patients from the National Institute of Neurological Disorders and Stroke (NINDS)-tPA trial database. Since baseline NIHSS scores of our patients were ≥16 except for one patient (NIHSS score of 13), we selected TPA-treated patients who had a NIHSS score of 16 or more. In the comparable NINDS trial's tPA-treated patients, mRS 0-2 at 3 months was observed in only 26%, which is much lower than our finding. When further restricted to patients with age ≥70 and NIHSS ≥16, the rate of mRS 0-2 further decreased to 16%. [3],[4],[5] A prior conventional angiography study demonstrated that more than 90% of patients with NIHSS ≥12 had an occlusion in ICA, M1, or basilar artery. [24] Therefore, the low rates of good outcome with intravenous TPA in patients with severe stroke must be attributed to a low recanalization rate in large vessel occlusions. [1],[2] These data suggest that for severe stroke with large vessel occlusion IA fibrinolysis should be considered.

The SHT of 20% in this study is higher than in other studies, but the mortality rate of 30% is comparable [Table 4]. Of the two SHTs, one SHT occurred in a patient who received neither intravenous TPA nor intra-arterial thrombolytic agent. He failed to achieve recanalization with thrombectomy and had a malignant hemispheric infarction involving whole ICA territory with massive hemorrhagic conversion. Therefore, the SHT in this patient might be attributed to a treatment failure rather than a thrombectomy-related complication. For asymptomatic hemorrhagic transformation, our frequency of 40% was modestly higher than those of other IA therapy studies and much greater than 6% of comparable NINDS cohorts.

In conclusion, the Solitaire device-assisted thrombectomy can achieve a high recanalization rate and potentially improves functional outcome with an acceptable safety in patients with large vessel occlusions. Well-designed trials should be undertaken to add this promising treatment to the arsenal of proven therapies for acute stroke.

 » References Top

1.Wolpert S, Bruckmann H, Greenlee R, Wechsler L, Pessin M, del Zoppo G. Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. The rt-PA Acute Stroke Study Group. AJNR Am J Neuroradiol 1993;14:3-13.  Back to cited text no. 1
2.Lee KY, Han SW, Kim SH, Nam HS, Ahn SW, Kim DJ, et al. Early recanalization after intravenous administration of recombinant tissue plasminogen activator as assessed by pre- and post-thrombolytic angiography in acute ischemic stroke patients. Stroke 2007;38:192-3.  Back to cited text no. 2
3.Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-7.  Back to cited text no. 3
4.Ingall TJ, O'Fallon WM, Asplund K, Goldfrank LR, Hertzberg VS, Louis TA, et al. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial. Stroke 2004;35:2418-24.  Back to cited text no. 4
5.Dachs RJ, Burton JH, Joslin J. A user's guide to the NINDS rt-PA stroke trial database. PLoS Med 2008;5:e113.  Back to cited text no. 5
6.Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: A randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999;282:2003-11.  Back to cited text no. 6
7.Ogawa A, Mori E, Minematsu K, Taki W, Takahashi A, Nemoto S, et al. Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: The middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan. Stroke 2007;38:2633-9.  Back to cited text no. 7
8.Lee M, Hong KS, Saver JL. Efficacy of intra-arterial fibrinolysis for acute ischemic stroke: Meta-analysis of randomized controlled trials. Stroke 2010;41:932-7.  Back to cited text no. 8
9.Jansen O, von Kummer R, Forsting M, Hacke W, Sartor K. Thrombolytic therapy in acute occlusion of the intracranial internal carotid artery bifurcation. AJNR Am J Neuroradiol 1995;16:1977-86.  Back to cited text no. 9
10.Zaidat OO, Suarez JI, Santillan C, Sunshine JL, Tarr RW, Paras VH, et al. Response to intra-arterial and combined intravenous and intra-arterial thrombolytic therapy in patients with distal internal carotid artery occlusion. Stroke 2002;33:1821-6.  Back to cited text no. 10
11.Arnold M, Nedeltchev K, Mattle HP, Loher TJ, Stepper F, Schroth G, et al. Intra-arterial thrombolysis in 24 consecutive patients with internal carotid artery T occlusions. J Neurol Neurosurg Psychiatry 2003;74:739-42.  Back to cited text no. 11
12.Eckert B, Kucinski T, Neumaier-Probst E, Fiehler J, Rother J, Zeumer H. Local intra-arterial fibrinolysis in acute hemispheric stroke: Effect of occlusion type and fibrinolytic agent on recanalization success and neurological outcome. Cerebrovasc Dis 2003;15:258-63.  Back to cited text no. 12
13.Smith WS, Sung G, Starkman S, Saver JL, Kidwell CS, Gobin YP, et al. MERCI trial investigators safety and efficacy of mechanical embolectomy in acute ischemic stroke: Results of the MERCI trial. Stroke 2005;36:1432-8.  Back to cited text no. 13
14.Smith WS. Safety of mechanical thrombectomy and intravenous tissue plasminogen activator in acute ischemic stroke. Results of the multi Mechanical Embolus Removal in Cerebral Ischemia (MERCI) trial, part I. AJNR Am J Neuroradiol 2006;27:1177-82.  Back to cited text no. 14
15.Smith WS, Sung G, Saver J, Budzik R, Duckwiler G, Liebeskind DS, et al. Mechanical thrombectomy for acute ischemic stroke: Final results of the Multi MERCI trial. Stroke 2008;39:1205-12.  Back to cited text no. 15
16.Penumbra Pivotal Stroke Trial Investigators. The penumbra pivotal stroke trial: Safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease. Stroke 2009;40:2761-8.  Back to cited text no. 16
17.Castano C, Dorado L, Guerrero C, Millan M, Gomis M, Perez de la Ossa N, et al. Mechanical thrombectomy with the Solitaire AB device in large artery occlusions of the anterior circulation: A pilot study. Stroke 2010;41:1836-40.  Back to cited text no. 17
18.Castano C, Serena J, Davalos A. Use of the New Solitaire (TM) AB device for mechanical thrombectomy when merci clot retriever has failed to remove the clot. A case report. Interv Neuroradiol 2009;15:209-14.  Back to cited text no. 18
19.Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-29.  Back to cited text no. 19
20.IMS Study Investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: The Interventional Management of stroke study. Stroke 2004;35:904-11.  Back to cited text no. 20
21.IMS II Trial Investigators. The Interventional Management of Stroke (IMS) II Study. Stroke 2007;38:2127-35.  Back to cited text no. 21
22.Higashida RT, Furlan AJ, Roberts H, Tomsick T, Connors B, Barr J, et al.; Technology Assessment Committee of the American Society of Interventional and Therapeutic Neuroradiology; Technology Assessment Committee of the Society of Interventional Radiology. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke. Stroke 2003;34:e109-37.  Back to cited text no. 22
23.Saver JL, Jahan R, Levy E, Jovin TG, Baxter B, Nogueira R, et al. Primary results of the SolitaireTM FR with the Intention for Thrombectomy (SWIFT) multicenter, randomized clinical trial. International Stroke Conference. Late Breaking Science Oral Abstracts, 2012.  Back to cited text no. 23
24.Fischer U, Arnold M, Nedeltchev K, Brekenfeld C, Ballinari P, Remonda L, et al. NIHSS Score and Arteriographic Findings in Acute Ischemic Stroke. Stroke 2005;36:2121-5.  Back to cited text no. 24


  [Figure 1], [Figure 2]

  [Table 1], [Table 2], [Table 3], [Table 4]

This article has been cited by
1 A 77-Year-Old Man With Large Vessel Acute Ischemic Stroke
Andrew Latimer,Jeffrey Bell,Elizabeth Powell,Peter V.R. Tilney
Air Medical Journal. 2015; 34(5): 230
[Pubmed] | [DOI]
2 Endovascular treatment of acute ischemic stroke – Own experience
Daniel Knap,Maciej Honkowicz,Tomasz Kirmes,Marcin Koronski,Mateusz Bukanski,Marzena Kysiak,Bartosz Kadlubicki,Izabela Dymon,Dominik Sieron,Jan Baron
Neurologia i Neurochirurgia Polska. 2015; 49(2): 81
[Pubmed] | [DOI]
3 Retrievable stent thrombectomy in the treatment of acute ischemic stroke: Analysis of a revolutionizing treatment technique
Brian P. Walcott,Kevin M. Boehm,Christopher J. Stapleton,Brijesh P. Mehta,Brian V. Nahed,Christopher S. Ogilvy
Journal of Clinical Neuroscience. 2013; 20(10): 1346
[Pubmed] | [DOI]


Print this article  Email this article
Online since 20th March '04
Published by Wolters Kluwer - Medknow